Last reviewed · How we verify
NCT05751733
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
NA trial testing Apatinib Mesylate in Gastrointestinal Stromal Tumors in 258 participants. Currently enrolling.
1 January 2026
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 258 |
| Start date | 1 February 2023 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Apatinib Mesylate
- Sunitinib, Imatinib dosage, Dasatinib, Reveratinib — full drug profile →
Conditions studied
- Gastrointestinal Stromal Tumors — all drugs for Gastrointestinal Stromal Tumors →
Sponsor
Xiangya Hospital of Central South University
Who can join
18 and older, any sex, with Gastrointestinal Stromal Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety of Apatinib compared with second-line treatment in advanced GIST patients with first-line TKI failure. The main questions it aims to answer are: * To explore the efficacy and safety of Apatinib compared with standard second-line treatment for GIST with advanced first-line TKI failure. * To explore the expression level and MVD value of VEGFR2 in GIST, and to explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST. Patients with advanced GIST were randomly included in the trial group and the control group at a ratio of 1:1.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives.
Catalano F, Cremante M, Dalmasso B, Pirrone C, et al · · 2023 · cited 6× · PMID 37046734 · DOI 10.3390/cancers15072074
Verify or expand the search:
- PubMed search for NCT05751733
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apatinib Mesylate
Trials testing the same drug.
- NCT06539091 — Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer · Phase 3 · not yet recruiting
- NCT06483282 — A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis i · Phase 2 · recruiting
- NCT05613478 — Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma · Phase 3 · recruiting
- NCT05524974 — Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant T · Phase 2 · not yet recruiting
- NCT05342389 — Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer · Phase 2 · unknown
Other recruiting trials for Gastrointestinal Stromal Tumors
Currently open trials in the same condition.
- NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
- NCT06326346 — GIST Oral Paclitaxel(Liporaxel) · Phase 2 · recruiting
- NCT06087263 — Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation · Phase 2 · active not recruiting
- NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
- NCT05905887 — Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor · Phase 2 · recruiting
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05751733 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 2 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05751733.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing